Featured Research

from universities, journals, and other organizations

Sniffing Out The Promise Of Anti-Angiogenesis Therapy

Date:
May 17, 1999
Source:
University Of Southern California
Summary:
A team of USC scientists led by Parkash Gill, M.D., have shown in a human clinical trial that a small peptide, in the form of a nose drop, may be a successful anti-angiogenesis treatment.

ATLANTA, May 16, 1999 -- A team of USC scientists led by Parkash Gill, M.D., have shown in a human clinical trial that a small peptide, in the form of a nose drop, may be a successful anti-angiogenesis treatment.

Gill's data on the anti-angiogenesis peptide IM862 in the treatment of Kaposi's Sarcoma (KS)-the most common cancer associated with HIV-will be presented at the annual meeting of the American Society of Clinical Oncology, and will be featured in a press conference on novel cancer therapies on Sunday, May 16, at 11 a.m.

In Phase II of the clinical trial of IM862-from which the data presented were taken-Gill, a professor of medicine and pathology at the University of Southern California School of Medicine, along with Peter Brooks, Ph.D., Jeffrey Weber, M.D., Ph.D., and Anil Tulpule, M.D., all from USC, treated 35 patients with an intranasal solution administered as a nose drop of IM862. They found that 37 percent of the patients showed a major response-either complete resolution of the KS lesions (4 patients) or partial reduction in tumor size (9 patients)-within six weeks of beginning treatment. In another 17 patients, the disease has not progressed for six months or longer.

"All this occurred with very few side effects," says Gill, "which were limited mostly to mild headaches."

IM862-now well into Phase III clinical trials-is among the first anti-angiogenesis drugs to get to this phase all on its own, says Gill. "Most of the other anti-angiogenic drugs are combined with chemotherapy," he notes. "This may end up being the way this family of drugs will be developed." (The chemicals which started the anti-angiogenesis debate-angiostatin and endostatin-have not yet reached Phase I trials.)

IM862, a thymic dipeptide, a small protein, was developed by Cytran, Inc., a private held company located in Kirkland, Wash. It does not go after tumor cells directly-in fact, says Gill, "it is not cytotoxic to any tumor cells." It inhibits blood vessel formation and/or modulates the immune system.

KS is treatable (though not curable) with conventional chemotherapy, but, notes Gill, "chemotherapy comes along with so much toxicity that people will only stay on it for a period of time before they literally get sick of it." IM862, on the other hand, may be taken for a prolonged period of time if the tumors' response remains positive.

In addition to being safe, IM862 is a small molecule that makes synthesis and production of the peptide fairly simple. It also makes nasal administration possible. "It can get over the nasal membrane intact," says Gill, so that more than 70 percent of the given dose winds up in the bloodstream. Because the peptide is destroyed by the stomach, it can't be put into pill form, says Gill. "And, obviously, administering the drug through a more convenient route is preferable," he adds.

"Unlike many other cancer drugs that must be given by injection, this peptide can be self administered by the patient as a nose drop," says Gill.

Perhaps an intriguing thing about anti-angiogenesis drugs like IM862 is that it works indirectly by altering the function of other cells. IM862, for instance, seems to interact with a number of different immune system cells once it has made its way into the body. The peptide appears to stimulate natural killer (NK) cells by enhancing production of the cytokine interleukin-12.

This immune stimulation, potent on its own, also has an anti-angiogenic effect, says Gill, "NK cells produce factors which are toxic to endothelial cells," he explains. Endothelial cells are the cells out of which blood vessels are made-and from which KS develops.

But IM862's effect on blood vessel formation reaches even further. Gill and his colleagues found that when chicken allantoic membrane was exposed to IM862 (the vessel-rich embryonic membrane is a standard tool for testing anti-angiogenic activity), blood vessel formation was blocked. Later they found that the blood vessel count in tumors implanted in mice was reduced when the tumor was treated with IM862.

Its main effect, says Gill, appears to be in reducing production of vascular endothelial growth factors, or VEGFs, and blocking the function of BFGF which Gill says are "major mediators of angiogenesis, tumor growth and spread. These growth factors are produced by tumors and the stroma around tumors."

And it does all this despite a half-life in the body of all of five minutes. "Obviously, that's too short a timespan for it to do anything directly," says Gill. "That's why we need to consider the secondary effects it causes: the decrease in VEGF production, the increase in IL12 production, the stimulation of natural killer cells and their products."

One of its secondary effects is on monocytes-white blood cells which are the precursors of macrophages. IM862 on its own isn't able to make a dent on the proliferation of endothelial cells. Add monocytes into the mix, however, and the peptide begins to make itself heard. Monocytes-immune cells that eventually develop into macrophages-secrete a number of growth factors, explains Gill, and hence have a significant role in blood vessel formation. When you treat a monocyte's chemical secretions-or supernatants-with IM862, the potency of the growth factors is reduced. "IM862 treated supernatants reduce endothelial cell proliferation by two-thirds," says Gill. "For patients with KS-and potentially a host of other cancers-that's all you need to reduce or even obliterate the disease."

Studies looking at IM862's efficacy in treating ovarian carcinoma and melanoma are also ongoing and studies of other cancers are planned.

"The initial idea of anti-angiogenesis therapy was to stop tumor growth and spread," says Gill. "But in the lab, we and others have seen that newly-formed vessels are susceptible to actual cell death if we deprive them of certain factors. That leads us to think that if we can destroy newly formed vessels, the cells dependent on them for their supply of nutrients will also die. And that is certainly what seems to be happening here."


Story Source:

The above story is based on materials provided by University Of Southern California. Note: Materials may be edited for content and length.


Cite This Page:

University Of Southern California. "Sniffing Out The Promise Of Anti-Angiogenesis Therapy." ScienceDaily. ScienceDaily, 17 May 1999. <www.sciencedaily.com/releases/1999/05/990517065004.htm>.
University Of Southern California. (1999, May 17). Sniffing Out The Promise Of Anti-Angiogenesis Therapy. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/1999/05/990517065004.htm
University Of Southern California. "Sniffing Out The Promise Of Anti-Angiogenesis Therapy." ScienceDaily. www.sciencedaily.com/releases/1999/05/990517065004.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Costs Keep Mounting

Ebola Costs Keep Mounting

Reuters - Business Video Online (Sep. 23, 2014) The WHO has warned up to 20,000 people could be infected with Ebola over the next few weeks. As Sonia Legg reports, the implications for the West African countries suffering from the disease are huge. Video provided by Reuters
Powered by NewsLook.com
Ebola Cases Could Reach 1.4 Million Within 4 Months

Ebola Cases Could Reach 1.4 Million Within 4 Months

Newsy (Sep. 23, 2014) Health officials warn that without further intervention, the number of Ebola cases in Liberia and Sierra Leone could reach 1.4 million by January. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Cases to Triple in Weeks Without Drastic Action

WHO: Ebola Cases to Triple in Weeks Without Drastic Action

AFP (Sep. 23, 2014) The number of Ebola infections will triple to 20,000 by November, soaring by thousands every week if efforts to stop the outbreak are not stepped up radically, the WHO warned in a study on Tuesday. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
5 Ways Men Can Prevent Most Heart Attacks

5 Ways Men Can Prevent Most Heart Attacks

Newsy (Sep. 23, 2014) No surprise here: A recent study says men can reduce their risk of heart attack by maintaining a healthy lifestyle, which includes daily exercise. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins